| Identification | Back Directory | [Name]
Beinaglutide | [CAS]
123475-27-4 | [Synonyms]
Benaglutide
Beinaglutide
L-Arginine, L-histidyl-L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-
L-Arginine, L-histidyl-L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglyc... | [Molecular Formula]
C149H225N39O46 | [MOL File]
123475-27-4.mol | [Molecular Weight]
3298.67 |
| Hazard Information | Back Directory | [Uses]
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH)[1][2]. | [in vivo]
Beinaglutide (0.6, 1.2, 2.4 mg/kg; s.c.; three times per day for 7 consecutive days) shows the ability of glycemic contro, inhibits food intake and weight loss in mouse[1].
Beinaglutide (150 μg/kg; s.c.; daily for 6 weeks) increases insulin sensitivity of adipocytes[2]. | Animal Model: | Wild-type male C57BL/6 mice and Male Lepob/Lepob (ob/ob) mice (ob/ob-NASH mouse model was induced by GAN diet)[1] | | Dosage: | 0.6, 1.2, 2.4 mg/kg | | Administration: | S.c.; three times per day for 7 consecutive days | | Result: | Significantly reduced blood glucose with dosedependence in C57BL/6 and ob/ob mice, dose dependently inhibits food intake and gastric Emptying, and significantly reduced body weight, food intake with dose-dependence. |
| Animal Model: | Eight-week-old male C57BL/6 mice[2] | | Dosage: | 150 μg/kg | | Administration: | S.c.; daily for 6 weeks | | Result: | Showed improved glucose tolerance and insulin sensitivity, decreased adipose tissue weight and adipocyte size and potentiated insulin sensitivity of adipocytes. |
| [References]
[1] Fang X, et al. Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model. Life Sci. 2021 Apr 1;270:118966. DOI:10.1016/j.lfs.2020.118966
[2] Zhang F, et al. Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice. iScience. 2021 Oct 30;24(12):103382. DOI:10.1016/j.isci.2021.103382 |
|
| Company Name: |
Combio (Suzhou) Ltd.
|
| Telephone: |
17751201929; 17751201929 |
| Website: |
http://www.combiosz.com/ |
| Company Name: |
Apextide Co Ltd
|
| Telephone: |
15300650552; 15300650552 |
| Website: |
http://www.apextide.com |
| Company Name: |
Linyi Changqing Chemical Co., LTD
|
| Telephone: |
+86-0532-55729510 +86-15853232676 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList1565479/0_EN.htm |
|